Summary
Boston Scientific Corporation (BSX) reported strong top-line growth for the third quarter and the first nine months of 2018. Net sales increased by 7.7% to $2.39 billion for the quarter and 9.4% to $7.26 billion for the nine-month period, driven by operational growth across its diverse business segments, including strong performance in Endoscopy, Urology and Pelvic Health, and Neuromodulation. The company also demonstrated solid profitability, with net income rising significantly. For the third quarter, net income was $432 million, or $0.31 per diluted share, compared to $283 million, or $0.20 per diluted share, in the prior year. For the nine-month period, net income was $1.285 billion, or $0.92 per diluted share, up from $719 million, or $0.52 per diluted share, in the prior year. The company made significant strategic acquisitions during the period, bolstering its product portfolio and market reach. While operational performance was robust, investors should note the substantial debt the company carries, although it remains compliant with its debt covenants. The company also faces ongoing litigation and regulatory scrutiny, which are common in the medical device industry and could impact future results.
Financial Highlights
49 data points| Revenue | $2.39B |
| Cost of Revenue | $672.00M |
| Gross Profit | $1.72B |
| SG&A Expenses | $870.00M |
| Operating Expenses | $1.33B |
| Operating Income | $388.00M |
| Interest Expense | $58.00M |
| Net Income | $432.00M |
| EPS (Basic) | $0.31 |
| EPS (Diluted) | $0.31 |
| Shares Outstanding (Basic) | 1.38B |
| Shares Outstanding (Diluted) | 1.40B |
Key Highlights
- 1Net sales increased by 7.7% to $2.39 billion in Q3 2018 and 9.4% to $7.26 billion for the first nine months of 2018.
- 2Net income significantly increased, reaching $432 million ($0.31/share) in Q3 2018 and $1.285 billion ($0.92/share) for the nine-month period.
- 3The company completed multiple strategic acquisitions in 2018, including Augmenix, Inc., VENITI, Inc., Claret Medical, Inc., Cryterion Medical, Inc., NxThera, Inc., and nVision Medical Corporation, strengthening its market position.
- 4Gross profit margin improved to 71.9% in Q3 2018 and 71.3% for the nine-month period, driven by cost reductions and favorable period expenses.
- 5Operating expenses, particularly R&D, saw an increase as the company continues to invest in innovation and product pipeline development.
- 6Total debt increased to $6.626 billion as of September 30, 2018, primarily due to debt issuances to fund acquisitions and operations, though the company remains compliant with debt covenants.
- 7The company experienced a significant decrease in cash provided by operating activities for the first nine months of 2018 ($291 million vs. $742 million in 2017), largely attributed to a payment for an IRS tax settlement.